Medscape

Clinical Significance of HIV Reverse-transcriptase Inhibitor-resistance Mutations

† Drugs combined with NRTIs or NRTIs/NNRTIs are not listed. NNRTIs: Non-nucleoside reverse-transcriptase inhibitors; NRTIs: Nucleos(t)ide analog reverse-transcriptase inhibitors. Drug-resistance amino ...
ascopubs.org

Comparison of genomic alterations in bladder urothelial tumors with and without telomerase reverse transcriptase promoter mutation using a next-generation sequencing assay.

Second primary lung cancer in the United States: 1992–2008. This is an ASCO Meeting Abstract from the 2017 Genitourinary Cancers Symposium. This abstract does not include a full text component.
ascopubs.org

Characterizing telomerase reverse transcriptase (TERT) promoter mutations (mut) across sex, race, and cancer types.

Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.
JSTOR Daily

Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment–Naive Patients and Response to Regimens Containing ...

Background. The presence of transmitted drug resistance mutations (TDRMs) in antiretroviral treatment (ART)–naive patients can adversely affect the outcome of ART. Methods. Resistance testing was ...
Medscape

Clinical Significance of HIV Reverse-transcriptase Inhibitor-resistance Mutations

The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).